PeptideSearch

Nicotinamide Mononucleotide

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-09-04

Also called NMN / beta-Nicotinamide Mononucleotide / MIB-626

A vitamin B3 relative the body turns into NAD+. Sold as a capsule or powder. Tested in people for walking speed, sleep and blood sugar.

The body turns nicotinamide mononucleotide into NAD+, so the two are often talked about as one thing. They are separate molecules, given in different ways: see what the research shows on NAD+.

Nicotinamide riboside is the other common building block sold for the same purpose. It has its own separate trials: see what the research shows on Nicotinamide Riboside.

The basics

What is it?
A close relative of vitamin B3. The body converts it into NAD+, the fuel-handling molecule inside cells. It is usually swallowed.
What do we know?
Several small placebo-controlled trials in older adults report higher blood NAD levels, and single trials report better walking speed or sleep.
What do we still not know?
Whether any of those short-term changes add up to living better or longer. The trials are small, brief and mostly in one age group.

Official status: Not nominated for 503A compounding · Checked 2026-09-04

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Not an FDA-approved medicine. It is sold as a dietary supplement, and the FDA has said it does not accept it as a lawful supplement ingredient because it has been studied as a drug. That is a separate legal question from pharmacy compounding, which it has never been put forward for.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

What happens next

A reading of the FDA nominated-substance lists and the FDA position on NMN as a supplement ingredient before any status is published.

Supplement rules and pharmacy compounding rules are different laws. Neither answer should be guessed from the other.

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for Nicotinamide Mononucleotide. Unsubscribe in one click.